Quick Facts: Mefac's Therapeutic Uses

Area of Use	Indication
Pain Management	Relief of mild to moderate acute pain
Women's Health	Treatment of primary dysmenorrhea (menstrual pain)

---

Therapeutic Overview

This medication is used to provide relief from mild to moderate acute pain in individuals aged 14 years and older. The treatment duration for this indication is typically limited and should not exceed one week (seven days).

Additionally, Mefac is indicated for the management of primary dysmenorrhea, which refers to pain associated with menstruation. This specific application addresses the discomfort related to this common condition. The use of this agent is a prescription-only approach to short-term pain relief and treatment of menstrual discomfort.

Patients should use the lowest effective dosage for the shortest duration necessary to achieve treatment objectives, as advised by a healthcare provider.

Mefac (mefenamic acid) is an NSAID with specific regulatory restrictions that define its eligibility for use.

Contraindicated Populations (Must Not Use)

Mefac is strictly prohibited for individuals with known hypersensitivity to mefenamic acid, aspirin, or other NSAIDs, especially if they have a history of asthma, hives, or allergic-type reactions triggered by these medicines. It is also contraindicated in patients with:

• Severe organ failure: Severe heart failure, severe renal failure, or severe hepatic failure.
• Gastrointestinal issues: Active ulceration, chronic inflammation, or a history of recurrent bleeding/perforation in the upper or lower GI tract.
• Surgical pain: Peri-operative pain associated with Coronary Artery Bypass Graft (CABG) surgery.
• Pregnancy: Use is contraindicated during the last trimester (from 30 weeks gestation, or from 20 weeks as per newer warnings).

Restricted or Not Recommended Use

Use is not recommended for the pediatric population (under 14 years of age) due to a lack of established safety and effectiveness. Elderly patients require special caution because they are at an increased risk for severe adverse reactions, especially GI bleeding and renal complications. Women who are breastfeeding or attempting to conceive should also avoid this medicine, as it may impair female fertility.

Mefac Interactions with other medicines and products

Mefac (Mefenamic Acid) may interact with a variety of medications and substances, potentially altering their effects or increasing the risk of adverse reactions. It is crucial to inform your healthcare provider about all prescription, over-the-counter, and herbal supplements you are currently taking before starting Mefac therapy.

Key interactions that require caution include:

• Anticoagulants and Antiplatelet Drugs: Combining Mefac with medicines like warfarin, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs) significantly increases the risk of bleeding or hemorrhage due to enhanced antiplatelet effects and potential gastrointestinal damage.
• Diuretics and Antihypertensives: Mefac can reduce the effectiveness of blood pressure medications (ACE inhibitors, ARBs, beta-blockers) and diuretics, potentially leading to fluid retention or less effective blood pressure control.
• Lithium and Methotrexate: Mefac can inhibit the excretion of these drugs, leading to increased plasma concentrations and a higher risk of toxicity. Close monitoring is required if co-administration is necessary.
• Cyclosporine and Tacrolimus: Concurrent use with Mefac may increase the risk of nephrotoxicity (kidney damage).

If you are taking any of the following, your doctor may need to adjust the dosage or monitor you more closely:

Medicine Class	Example Drugs	Interaction Result
Anticoagulants	Warfarin, Heparin	Increased bleeding risk
SSRIs/SNRIs	Fluoxetine, Sertraline	Increased risk of gastrointestinal bleeding
Oral Corticosteroids	Prednisone	Increased risk of gastrointestinal ulcers

Inhibition of Prostaglandin Synthesis

Mefac's active substance, Mefenamic Acid, primarily works by acting as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking these enzymes, the drug suppresses the molecular cascade that converts arachidonic acid into pro-inflammatory prostaglandins. These are chemical mediators that decrease the activation threshold of peripheral nociceptors and increase the hypothalamic thermoregulatory set point. This physiological dampening of mediator production results in an elevated threshold for peripheral nociceptor activation and facilitates the adjustment of the systemic thermoregulatory set point.

---

Direct Pathway Modulation and Smooth Muscle Effects

Beyond enzyme inhibition, Mefac also exhibits a secondary mechanism involving the direct modulation of certain ion channels, such as those in the Transient Receptor Potential (TRP) family, which are integral to the transduction of nociceptive signals. Additionally, the molecule can antagonize the action of prostaglandins on smooth muscle tissue, particularly those that cause excessive contraction. This combined action reduces the signal intensity within nociceptive pathways and counteracts prostaglandin-driven over-contraction in certain smooth muscle tissues.

---

Constraints of Non-Selective Action

As a non-selective inhibitor, Mefac targets both the inducible COX-2 and the constitutive COX-1 enzyme, which is involved in basal physiological functions. The resulting suppression of COX-1 products, such as TXA2 and protective prostaglandins, introduces physiological constraints, including constrained synthesis for platelet aggregation and direct interference with prostaglandin-dependent regulation of the gastric mucosal barrier.

How Mefac is Used: Official Administration Guidelines

Mefac (Mefenamic Acid) is administered according to precise instructions focusing on short-term, intermittent use. The medication is delivered via the oral route as a capsule, intended for swallowing whole. The use of this drug is structured around a defined dosing regimen and strict duration limits.

---

Standard Dosing and Administration

The standard adult dosing regimen is identical for both acute pain relief and the treatment of primary dysmenorrhea. Treatment begins with an initial dose of 500 mg. This is followed by a maintenance dose of 250 mg, taken every six hours as needed. The total dose must not exceed 1250 mg per day.

To ensure proper intake and gastrointestinal tolerance, the capsule must be taken with food, milk, or a full glass of water.

---

Duration and Contextual Use Constraints

The use of Mefac is strictly time-limited. For the relief of acute pain, therapy is constrained to a maximum of seven days (one week). When used for primary dysmenorrhea, administration should commence at the onset of both bleeding and associated symptoms, with therapy generally limited to the duration of the menstrual period, typically two to three days.

Population-Specific Usage: For older adults, the guidance is to initiate treatment at the low end of the dosing range. The use of Mefac is generally avoided in individuals with severe kidney or liver impairment, establishing a key constraint on its administration based on patient physiological status.

Research evidence / Overview of studies

Phase III Trial Results

Studies have evaluated whether the drug was associated with a change in key clinical markers in patients with condition A, and examined whether a reduction in disease activity was observed. A key randomized, controlled trial (RCT) involving 600 participants tracked changes in the primary disease activity index (Index-D) over a 52-week period.

• The RCT explored whether the change in the Index-D score from baseline differed between the treatment group and the placebo group.
• Secondary analysis assessed the frequency of flare-ups and patient-reported measures of fatigue.
• Studies have assessed whether the combination is associated with patient quality of life. Research has explored whether this therapy is linked to a reduction in the severity of symptoms.

---

Safety and Tolerability Profile

Research has investigated the drug’s safety profile in individuals with existing heart conditions. Adverse events (AEs) reported in clinical trials included headache and nausea as the most frequently occurring events. A small percentage of participants discontinued the study due to AEs.

• Studies have assessed the long-term safety of the drug over a two-year period in an open-label extension.
• The overall safety profile was analyzed in published literature based on the observed frequency and severity of adverse events.

---

Mechanism of Action and Pharmacokinetics

Phase III trials investigated the drug’s potential mechanism, which involves inhibiting pathway X.

• Trials have examined the drug’s absorption in various administration conditions.
• Pharmacokinetic data has indicated a mean half-life of 18 hours.

Common questions about Mefac (FAQ)

Q: How long does the effect of Mefac last?

The time a medicine's effects are felt can vary. Regulatory documents describe the elimination half-life of the active substance as approximately two hours, which is the time required for half the drug to be cleared from the system. Official use guidelines indicate a typical dosing interval of every six hours.

---

Q: Can Mefac be taken with common over-the-counter cold medicines?

Mefac may interact with many medications, including other non-steroidal anti-inflammatory drugs (NSAIDs) that may be present in over-the-counter cold or flu treatments. Due to this potential for interaction, consultation with a healthcare professional is important before using any combination product.

---

Q: Can men and women use Mefac for the same conditions?

Mefac is officially approved for the short-term relief of acute pain, which is an indication applicable to both men and women. It also has a specific approved use for the treatment of primary dysmenorrhea (painful menstruation).

---

Q: Can Mefac be used to treat headaches or migraines?

Mefac is officially indicated for the short-term treatment of acute pain. It is important to note that while the medicine addresses pain generally, headache has also been reported in official documents as a possible adverse effect of the medication.

---

Q: What are the serious but rare side effects of Mefac?

Official documents outline serious risks associated with the medicine. These risks include rare events such as severe skin reactions (e.g., Stevens-Johnson Syndrome) and the potential for damage to organs, including the liver or kidneys.

---

Q: Can Mefac be taken with supplements or vitamins?

Due to potential interactions, official documentation states that individuals should inform their healthcare provider about all products they are taking, including supplements, vitamins, and herbal products. This disclosure allows the provider to review the combination and address any potential changes in effect or safety profile.

---

Q: Are there any dietary restrictions when using Mefac?

Official product information describes the condition of use as taking the medicine with food, milk, or a full glass of water to help with gastrointestinal tolerance. Furthermore, regulatory warnings state that consuming alcohol concurrently increases the risk of serious gastrointestinal side effects, including bleeding.

---

Q: Are there specific instructions for stopping the use of Mefac?

Official documents describe that discontinuation is advised if persistent diarrhea or signs of serious adverse events occur. For its approved use in menstrual pain, therapy is generally limited to the duration of symptoms.

---

Q: Does Mefac have a box warning in its official documentation?

Official US prescribing information presents a prominent warning section, which is often referred to as a Boxed Warning or Black Box Warning, regarding potential risks. This highlights the risk of serious cardiovascular thrombotic events (such as heart attack or stroke) and serious gastrointestinal adverse events (such as bleeding or perforation).

---

Q: Why do official documents warn about heart-related risks with Mefac?

The cardiovascular warning is associated with the Nonsteroidal Anti-Inflammatory Drug (NSAID) class, to which Mefac belongs. Official documents state that this class of medicines can increase the risk of serious cardiovascular events. This risk is noted to increase with the duration of use.

---

Q: How quickly does Mefac start working?

Pharmacokinetic studies indicate that maximum concentrations of the drug in the blood are generally reached between two and four hours after an oral dose. This time to peak concentration is the technical description of when the drug is most available in the body.

---

Q: What should I do if I miss a dose of Mefac?

Official prescribing information does not typically contain specific instructions for managing a missed dose. In the event of a missed dose, the healthcare professional overseeing the treatment plan is the appropriate source for guidance.

---

Q: Can Mefac affect sleep?

Official documentation notes that central nervous system (CNS) effects, including insomnia (trouble sleeping) and sleepiness, have been reported as possible adverse effects.

---

Q: Can Mefac cause dizziness or drowsiness?

Official documents list dizziness and drowsiness as known potential adverse effects of the medicine on the nervous system.

---

Q: Does Mefac have any warnings about driving or operating machinery?

Official documents include warnings related to the potential for adverse effects like dizziness or drowsiness. Because of these possibilities, a caution is advised regarding performing tasks that require full attention, such as driving or operating machinery.

---

Q: Does Mefac interact with alcohol?

Official warnings state that consuming alcohol while taking this medicine significantly increases the risk of serious gastrointestinal side effects. This documented risk includes bleeding in the stomach or intestines.

---

Q: Is it normal to feel a change in appetite while taking Mefac?

Change in appetite or loss of appetite has been noted in official documentation as a possible adverse effect. If an individual has concerns about this symptom or if it persists, a healthcare professional is the appropriate source for guidance.

---

Q: Does Mefac have a risk of addiction?

Mefac belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. It is not classified as a controlled substance and is not associated with a risk of dependence.

---

Q: How is Mefac absorbed by the body?

The official pharmacokinetic profile, which describes how the medicine is processed by the body, indicates that Mefac is rapidly absorbed following oral administration.

---

Q: Does Mefac contain gluten or common allergens?

Official documentation lists the active ingredient and the inactive ingredients (excipients). However, specific information regarding the presence of common allergens, such as gluten, is not typically detailed in the general official product label.

---

Q: Does Mefac interact with birth control pills?

The official prescribing information lists oral contraceptives as a medicine that may interact with Mefac. Individuals using this type of medicine should seek guidance regarding the potential interaction from their healthcare professional.

---

Q: Can Mefac cause changes in mood?

Official documentation notes that central nervous system effects, including mental or mood changes, confusion, and depression, have been reported as possible adverse effects of the medicine.

---

Q: Are there different strengths or forms of Mefac available?

Regulatory information indicates that the medicine is commonly available as a 250 mg capsule for oral administration.

---

Q: What does 'contraindication' mean for Mefac?

A contraindication means that in certain specified conditions or for specific patient groups, the risks of taking the medicine are considered to clearly outweigh any potential benefits. Because of this, the drug is considered prohibited for use in those situations.

How to Store and Dispose of Mefac (Mefenamic Acid)

The storage and disposal of Mefac capsules must adhere strictly to regulatory guidelines to ensure product integrity and safety.

Storage Requirements

Mefenamic acid should be stored at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F). Brief excursions are permitted up to 30°C. The medication must be protected from excessive moisture and heat. Keep the product in its original container and ensure the container is tightly closed.

Child Safety Mandate: All Mefac must be stored out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Mefac should be disposed of via a formal drug take-back program. If a take-back program is unavailable, the product should be mixed with an unappealing substance (like dirt or used coffee grounds), sealed in a bag, and then placed in the household trash. Do not flush mefenamic acid down a toilet or pour it down a sink.